AI Study: Synthetic Cannabinoid + Favipiravir Presents Viable Treatment Against Viral Infections, Including COVID
AI Study: Synthetic Cannabinoid + Favipiravir Presents Viable Treatment Against Viral Infections, Including COVID
Tetra Bio-Pharma Inc. (OTCQB:TBPMF) (TSX:TBP) (FRA:JAM1), announced results from the study of Onternabez combined with Favipiravir against ARDS (acute respiratory distress syndrome), sepsis, and COVID-19 through PREPAiRE, an AI powered platform which purposely integrates target identification, validation, lead discovery optimization, drug synthesis, and preclinical testing.
利樂生物製藥公司。(場外交易代碼：TBPMF)(多倫多證券交易所代碼：TBP)(法蘭克福證券交易所股票代碼：JAM1)，宣佈Onternabz的研究結果 與法比拉韋聯合應用針對ARDS(急性呼吸窘迫綜合徵)、膿毒症和新冠肺炎做好準備，一個艾動力平臺，有目的地集成目標識別、驗證、線索發現優化、藥物合成和臨牀前測試。
Results from the study demonstrate that Tetra's investigational therapeutic, ARDS-003, which contains the active pharmaceutical ingredient Onternabez, acts against various ARDS and sepsis targets, such as IL-6 and IL-8. Onternabez plays an important role in mitigating the inflammatory response in various targets of inflammatory conditions.
研究結果表明，利樂的研究治療藥物ARDS-003含有有效的藥物成分Onternabez，可對抗各種ARDS和膿毒症靶點，如IL-6和IL-8。恩替那貝茲在減輕炎症條件下不同靶點的炎症反應方面起着重要作用。
Favipiravir acts against different SARS-CoV-2 targets, such as spike glycoprotein and nucleoprotein. The interaction between Favipiravir and Onternabez against SARS-COV-2 yields a positive molecule synergy probability which is considered significant and justifies the combination of the two drugs to create a new therapeutic that is expected to be beneficial to increase treatment efficacy and reduce the duration of disease. Favipiravir can control the source of infection. Onternabez would contribute to the antiviral efficacy and can control the result of infection (i.e., the inflammatory response).
法韋拉韋針對SARS-CoV-2的不同靶點發揮作用，如刺激性糖蛋白和核蛋白。Favipiravir和Onternabz之間針對SARS-COV-2病毒的相互作用產生了一個積極的分子協同概率，這被認為是重要的，並證明將這兩種藥物結合起來創造一種新的治療方法是合理的，預計將有利於提高治療效率和縮短病程。法維拉韋可以控制感染源。恩替那貝茲有助於抗病毒療效，並可以控制感染的結果(即炎症反應)。
Dr. Guy Chamberland, CEO and chief regulatory officer at Tetra stated "We are very pleased by these artificial intelligence results as well as the recent positive results from the PIONEER trial. This underscores our commitment with Cellvera to developing an innovative combination drug candidate to combat viral diseases. We are more excited than ever about our collaboration with Cellvera and the possibility of delivering the next scientific breakthroughs."
蓋伊·錢伯蘭博士利樂首席執行官兼首席監管官表示：“我們對這些人工智能的結果以及最近先鋒試驗的積極結果感到非常高興。這突顯了我們對Cellvera開發一種創新的候選組合藥物來對抗病毒疾病。我們比以往任何時候都對我們與Cellvera的合作以及實現下一步科學突破的可能性感到興奮。“
Cannabinoids and COVID-19
大麻素和新冠肺炎
According to IUPHAR/BPS Guide to pharmacology, Onternabez is a form of synthetic cannabinoid, which acts as a CB2 receptor agonist and has anti-inflammatory activity. Recent research has shown that natural cannabinoids can be effective against COVID-19 too. Cannabinoid acids in hemp - cannabigerolic acid, or CBGA, and cannabidiolic acid, also known as CBDA have the ability to bind to the SARS-CoV-2 spike protein – the virus that causes COVID-19. By binding to the spike protein, these acids can block the virus from reaching into cells and causing infection.
根據IUPHAR/BPS藥理學指南，Onternabiz是一種合成大麻素，其作用是CB2受體激動劑，具有抗炎活性。最近的研究表明，天然大麻素也可以有效地對抗新冠肺炎。大麻中的大麻酸-大麻酚酸和大麻二酚酸，也被稱為CBDA-能夠與導致新冠肺炎的病毒SARS-CoV-2刺突蛋白結合。通過與刺突蛋白結合，這些酸可以阻止病毒進入細胞並導致感染。
Get your daily dose of cannabis news on Benzinga Cannabis. Don't miss out on any important developments in the industry.
獲取您的每日大麻用量新聞 在本辛加大麻上。不要錯過對該行業任何重要發展的期望。
Photo: Courtesy of CNW Group/Tetra Bio-Pharma Inc.
圖片來源：CNW集團/利樂生物製藥公司。
Related News
相關新聞
Tetra Bio-Pharma Announces Second Closing Of Financing With Alpha Blue Ocean
利樂生物製藥公司宣佈與阿爾法藍海公司第二次完成融資
Tetra Partners With Cellvera To Develop An Oral Treatment For COVID-19
利樂與賽爾維拉合作開發新冠肺炎的口服療法
Preclinical Trial Results Confirm Targeting Type 2 Cannabinoid Receptors Helps Relieve Sepsis-Related Condition
臨牀前試驗結果證實靶向2型大麻素受體有助於緩解膿毒症相關疾病
譯文內容由第三人軟體翻譯。